Pharmaceutical Excipient Quality Agreement Formulation & Clause Guide
Guiding excipient manufacturers to draft and negotiate Quality Agreements per IPEC rules, detailing change notification windows and audit access.
An excipient Quality Agreement is a legal document defining QMS responsibilities between drug manufacturers and excipient suppliers. Drafting must align with IPEC guidelines. Key clauses include: defining "major changes" (site moves, equipment swaps, solvent changes) and setting mandatory notification windows (typically 180 days beforehand); detailing OOS and deviation report times; and mapping buyer onsite audit frequencies.
Core Elements of an IPEC-Compliant Quality Agreement
The Quality Agreement must remain independent of commercial purchase orders. Its core mission is setting up the GMP compliance boundaries.
- Change Control: notification deadlines for changes in synthesis routes, containers, or specifications
- Non-conformance: mapping coordination duties during batch scrap, recalls, or regulatory audits
- Records retention: legal duties to retain production logs, chromatograms, and stability tests for 5-7 years
FAQ
What is the recommended change notification window?+
Per IPEC guidelines, major changes require 180 days advance written notice to allow drug firms to run compatibility evaluations or file variations. Moderate changes usually require a 90-day notice.
Next steps
If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.
